Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence

[1]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[2]  N. Brünner,et al.  Expression of urokinase plasminogen activator, its receptor and type‐1 inhibitor in malignant and benign prostate tissue , 2005, International journal of cancer.

[3]  B. Nielsen,et al.  Reduced metastasis of transgenic mammary cancer in urokinase‐deficient mice , 2005, International journal of cancer.

[4]  J. Massagué,et al.  G1 cell-cycle control and cancer , 2004, Nature.

[5]  N. Fusenig,et al.  Friends or foes — bipolar effects of the tumour stroma in cancer , 2004, Nature Reviews Cancer.

[6]  R. DePinho,et al.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. , 2004, Cancer cell.

[7]  R. Parsons.  Human cancer, PTEN and the PI-3 kinase pathway. , 2004, Seminars in cell & developmental biology.

[8]  Reuven Agami,et al.  A large-scale RNAi screen in human cells identifies new components of the p53 pathway , 2004, Nature.

[9]  Peter F M Choong,et al.  Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. , 2003, Clinical orthopaedics and related research.

[10]  H. Hanafusa,et al.  PTEN Induces Cell Cycle Arrest by Decreasing the Level and Nuclear Localization of Cyclin D1 , 2003, Molecular and Cellular Biology.

[11]  R. Bernards,et al.  Reversal of Senescence in Mouse Fibroblasts through Lentiviral Suppression of p53* 210 , 2003, The Journal of Biological Chemistry.

[12]  J. Foekens,et al.  Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression , 2003, Thrombosis and Haemostasis.

[13]  S. DeRuiter,et al.  Simultaneous inhibition of GSK3α and GSK3β using hairpin siRNA expression vectors , 2003 .

[14]  D. Dinh,et al.  Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells , 2003, Oncogene.

[15]  R. Bernards,et al.  Stable suppression of tumorigenicity by virus-mediated RNA interference. , 2002, Cancer cell.

[16]  F. McCormick,et al.  The RB and p53 pathways in cancer. , 2002, Cancer cell.

[17]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[18]  R. Bernards,et al.  E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. , 2002, Cancer cell.

[19]  G. Ayala,et al.  Reactive stroma in prostate cancer progression. , 2001, The Journal of urology.

[20]  A. V. van Rossum,et al.  Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions. , 2000, Genes & development.

[21]  W. Hahn,et al.  Genes involved in senescence and immortalization. , 2000, Current opinion in cell biology.

[22]  T. Jacks,et al.  Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. , 2000, Genes & development.

[23]  B. Kennedy,et al.  NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. , 2000, Genes & development.

[24]  D. Notterman,et al.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. , 2000, Genes & development.

[25]  P. Andreasen,et al.  The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.

[26]  M. Serrano,et al.  Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras , 1999, Oncogene.

[27]  V. Weaver,et al.  Tissue structure, nuclear organization, and gene expression in normal and malignant breast. , 1999, Cancer research.

[28]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[29]  C. Sherr,et al.  Tumor surveillance via the ARF-p53 pathway. , 1998, Genes & development.

[30]  Wenyi Wei,et al.  Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. , 1997, Science.

[31]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[32]  J. Shay,et al.  Altered expression of plasminogen activator and plasminogen activator inhibitor during cellular senescence , 1996, Experimental Gerontology.

[33]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[34]  P. Higgins,et al.  Differential growth state‐dependent regulation of plasminogen activator inhibitor type‐1 expression in senescent IMR‐90 human diploid fibroblasts , 1995, Journal of cellular physiology.

[35]  A. Balmain,et al.  Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors. , 1995, Cancer research.

[36]  C Roskelley,et al.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Otte,et al.  Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. , 1995, Nucleic acids research.

[38]  G. Hannon,et al.  Cloning and characterization of murine p16INK4a and p15INK4b genes. , 1995, Oncogene.

[39]  A. Copeta,et al.  Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts. , 1994, Experimental cell research.

[40]  M. Cole,et al.  The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1 , 1990, Molecular and cellular biology.

[41]  V. Tkachuk,et al.  Plasminogen Activators in Vascular Remodeling and Angiogenesis , 2004, Biochemistry (Moscow).

[42]  N. Brünner,et al.  Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. , 2001, Cancer research.